KAT2A and acute myeloid leukemia: KAT2A acetylates CCAAT/enhancer-binding protein alpha (C/EBPα)at K298 and K302 in human myeloid cell lines, reducing the DNA-bindingability of C/EBPα and repressing its transcriptionalactivity[82].Acetylation of C/EBPα is increased in human AML.